Clinical trial / 2010
Saffron supplementation improved cognitive function in patients with mild to moderate Alzheimer's disease.
In a 16-week randomized, double-blind, placebo-controlled trial, 46 patients with mild to moderate Alzheimer's disease received 30 mg daily of saffron or a placebo. Saffron produced significantly better cognitive outcomes than placebo on the ADAS-cog scale (P = 0.04) and clinical dementia rating (P = 0.04). No significant differences between groups were observed for adverse events.
- Study type
- Randomized controlled trial
- Who was studied
- 46 patients with mild to moderate Alzheimer's disease
- What was measured
- Cognitive function and dementia rating scores
THE PAPER
Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. J Clin Pharm Ther, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.